Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823853 | 0.91 | ABCB1 (0.44) | ABCB1PPARGCA2CA9PPARA | |
| SCHEMBL1828106 | 0.89 | PPARG (0.41) | PPARGPPARAMMP1ACACBMTNR1A | |
| SCHEMBL1825966 | 0.86 | ABCB1 (0.47) | ABCB1CA2CA9MTNR1AMTNR1B | |
| SCHEMBL1824720 | 0.86 | ABCB1 (0.39) | ABCB1PPARGCA2CA9PPARA | |
| SCHEMBL1823626 | 0.85 | PPARG (0.39) | PPARGPPARAACACBMTNR1AMTNR1B | |
| SCHEMBL1825427 | 0.85 | PPARG (0.46) | PPARGCA2CA9PPARAACACB | |
| SCHEMBL1826056 | 0.84 | SYK (0.49) | ABCB1PPARGCA2CA9PPARA | |
| SCHEMBL1824868 | 0.83 | PPARG (0.42) | ABCB1PPARGCA2CA9PPARA | |
| SCHEMBL1824192 | 0.83 | ABCB1 (0.38) | ABCB1PPARGCA2CA9PPARA | |
| SCHEMBL1822326 | 0.83 | ATM (0.50) | ABCB1PPARGCA2CA9PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161254-B1 | Intermediate for preparing a biaryl compound | SUMITOMO CHEMICAL CO (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-1481967-B1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2161254-A1 | Intermediate for preparing a biaryl compound | Sumitomo Chemical Company, Limited (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | ABCB1 1436/4885PPARG 3864/4885CA2 730/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | ABCB1 209/4885PPARG 2131/4885CA2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.